GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » ROE % Adjusted to Book Value

Silk Road Medical (FRA:2OW) ROE % Adjusted to Book Value : -6.30% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical ROE % Adjusted to Book Value?

Silk Road Medical's ROE % for the quarter that ended in Jun. 2024 was -44.19%. Silk Road Medical's PB Ratio for the quarter that ended in Jun. 2024 was 7.01. Silk Road Medical's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -6.30%.


Silk Road Medical ROE % Adjusted to Book Value Historical Data

The historical data trend for Silk Road Medical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical ROE % Adjusted to Book Value Chart

Silk Road Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -2.69 -2.92 -3.76 -11.21

Silk Road Medical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.31 -8.86 -10.88 -7.62 -6.30

Competitive Comparison of Silk Road Medical's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Silk Road Medical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silk Road Medical's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's ROE % Adjusted to Book Value falls into.



Silk Road Medical ROE % Adjusted to Book Value Calculation

Silk Road Medical's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-34.86% / 3.11
=-11.21%

Silk Road Medical's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.19% / 7.01
=-6.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silk Road Medical ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Silk Road Medical Business Description

Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical Headlines

No Headlines